CME Group director awarded 645 shares in stock grant

Benesh Kathryn reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Benesh Kathryn reported acquisition or exercise transactions in this Form 4 filing.

CME Group Inc. director Kathryn Benesh received an equity award of 645 shares of Class A common stock at $225.00 per share. The shares were granted as part of the company’s annual equity compensation program for non-employee directors under the CME Group Director Stock Plan and are fully vested with no further vesting conditions. Following this grant, she holds a total of 2,751.948 Class A shares directly.

Insider Trade Summary

Grant/Award: 645 shares

Grant/Award 1 txn

Insider Benesh Kathryn

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock Class A	645	$225.00	$145K

Holdings After Transaction: Common Stock Class A — 2,751.948 shares (Direct)

Footnotes (1)

1. F1. Represents a grant of fully vested shares of Class A Common Stock issued to the Reporting Person as part of the Issuer's annual equity compensation program for non-employee directors under the CME Group Director Stock Plan. These shares are not subject to any vesting conditions.

Key Figures

Equity award size: 645 shares Grant value per share: $225.00 per share Post-transaction holdings: 2,751.948 shares

3 metrics

Equity award size 645 shares Grant of Class A common stock to director

Grant value per share $225.00 per share Reported price for equity award shares

Post-transaction holdings 2,751.948 shares Total Class A shares held directly after grant

Key Terms

annual equity compensation program, non-employee directors, CME Group Director Stock Plan, fully vested shares

4 terms

annual equity compensation program financial

"issued to the Reporting Person as part of the Issuer's annual equity compensation program for non-employee directors"

non-employee directors financial

"annual equity compensation program for non-employee directors under the CME Group Director Stock Plan"

Non-employee directors are board members who do not work for the company as salaried employees and usually do not hold day-to-day management roles. They act like outside referees or independent coaches, providing oversight, asking tough questions, and protecting shareholders’ interests; investors care because these directors help ensure management is accountable, reduce conflicts of interest, and influence decisions that affect company strategy and long-term value.

CME Group Director Stock Plan financial

"under the CME Group Director Stock Plan. These shares are not subject to any vesting conditions."

fully vested shares financial

"Represents a grant of fully vested shares of Class A Common Stock"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CME (CME) director Kathryn Benesh report in this Form 4?

Director Kathryn Benesh reported receiving 645 fully vested shares of CME Group Class A common stock. The award was granted as part of CME’s annual equity compensation program for non-employee directors under the CME Group Director Stock Plan.

What is the size and price of the CME (CME) stock award to Kathryn Benesh?

Kathryn Benesh was awarded 645 shares of CME Group Class A common stock at a reported value of $225.00 per share. This award reflects equity compensation, not an open-market stock purchase or sale by the director.

Are the CME (CME) shares granted to Kathryn Benesh subject to vesting?

The 645 shares granted to Kathryn Benesh are fully vested and not subject to any vesting conditions. This means she has immediate rights to the shares under the company’s director equity compensation program.

How many CME (CME) shares does Kathryn Benesh hold after this transaction?

After receiving the 645-share equity award, Kathryn Benesh holds a total of 2,751.948 shares of CME Group Class A common stock directly. This figure reflects her updated ownership position following the reported grant.

What is the purpose of the CME (CME) equity grant reported by Kathryn Benesh?

The grant represents annual equity compensation for a non-employee director under the CME Group Director Stock Plan. It is intended as part of director remuneration, aligning director interests with shareholders through direct stock ownership in CME Group.

Was Kathryn Benesh’s CME (CME) transaction an open-market buy or sell?

The filing shows a grant coded as an acquisition (Code A), not an open-market buy or sell. The 645 shares were issued by CME Group as compensation, rather than being purchased or sold on the open market by the director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/29/2026 - 04:08 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Benesh Kathryn

(Last) (First) (Middle)

20 SOUTH WACKER DR.

(Street)

CHICAGO ILLINOIS 60606

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CME GROUP INC. [ CME ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock Class A	06/25/2026		A(1)		645	A	$225	2,751.948	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of fully vested shares of Class A Common Stock issued to the Reporting Person as part of the Issuer's annual equity compensation program for non-employee directors under the CME Group Director Stock Plan. These shares are not subject to any vesting conditions.

Remarks:

	/s/ Elizabeth Hensen, as Attorney-in-Fact for Kathryn Benesh	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)